Chih-Chiang Chen

Chih-Chiang Chen

Auto-generated profile, based on publicly available information

Chih-Chiang Chen

Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Dermatology, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in JID Innovations
Verified
Journal Article
Open access
CLChing-Wen Lin
Ching-Wen Lin
CCChih-Chiang Chen
Chih-Chiang Chen
WHWen-Yen Huang
Wen-Yen Huang
YCYen-Yu Chen
Yen-Yu Chen
SCShiou-Ting Chen
Shiou-Ting Chen
SCShun-Cheng Chang
Shun-Cheng Chang
Diabetic wounds exhibit chronic inflammation and delayed tissue proliferation or remodeling, mainly owing to prolonged proinflammatory (M1) macrophage activity and defects in transition to prohealing/proremodeling (M2a/M2c; CD206+ and/or CD163+) macrophages. We found that topical treatment with ON101, a plant-based potential therapeutic for diabetic foot ulcers, increased M2c-like (CD163+ and CD206+) cells and suppressed M1-like cells, altering the inflammatory gene profile in a diabetic mouse model compared with that in the controls. An in vitro macrophage-polarizing model revealed that ON101 directly suppressed CD80+ and CD86+ M1-macrophage polarization and M1-associated proinflammatory cytokines at both protein and transcriptional levels. Notably, conditioned medium collected from ON101-treated M1 macrophages reversed the M1-conditioned medium‒mediated suppression of CD206+ macrophages. Furthermore, conditioned medium from ON101-treated adipocyte progenitor cells significantly promoted CD206+ and CD163+ macrophages but strongly inhibited M1-like cells. ON101 treatment also stimulated the expression of GCSF and CXCL3 genes in human adipocyte progenitor cells. Interestingly, treatment with recombinant GCSF protein enhanced both CD206+ and CD163+ M2 markers, whereas CXCL3 treatment only stimulated CD163+ M2 macrophages. Depletion of cutaneous M2 macrophages inhibited ON101-induced diabetic wound healing. Thus, ON101 directly suppressed M1 macrophages and facilitated the GCSF- and CXCL3-mediated transition from M1 to M2 macrophages, lowering inflammation and leading to faster diabetic wound healing.

25 March 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CCChih‐Chiang Chen
Chih‐Chiang Chen
YCYun‐Ting Chang
Yun‐Ting Chang
HLHan‐Nan Liu
Han‐Nan Liu
YCYi-Ju Chen
Yi-Ju Chen
Alopecia areata (AA) is an organ‐specific autoimmune disorder. Defective immune system related disorders are prone to increase the risk of cancer formation. However, the association among AA and variety of cancer types had never been studied. A nationwide population‐based matched cohort study was conducted to evaluate the cancer risk in patients with AA. Records from Taiwan National Health Insurance Research Database were analyzed. Cases of AA from 1997 to 2013 and cancers registered in the catastrophic illness profile from the same time period were collected. The standard incidence ratio (SIR) of each cancer was calculated. In total, 2099 cancers among 162,499 patients with AA and without prior cancers were identified. The overall cancer risks in AA patients were slightly decreased, especially among male subjects (SIR: 0.89). Refer to individual cancer, the cancer risk of nonmelanoma skin cancer (NMSC) (SIR: 0.59), upper GI cancer (SIR: 0.70), liver cancer (SIR: 0.82), uterine, and cervix cancer (SIR: 0.84) were significantly lower in patients with AA. In contrast, AA patients were inclined to have lymphoma, breast cancer, kidney, and urinary bladder cancer with the SIR of 1.55, 2.93, and 2.95, respectively. Age stratified analyses revealed female AA patients younger than 50 years old have even higher risk of breast cancer (SIR: 3.37). Further sensitivity analysis showed similar results after excluding major autoimmune disorders. Cancer risk in AA patients is organ specific, and it is not associated with the underlying autoimmune disorders in patients with AA.

18 August 2025 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
YWYu-Ching Wang
Yu-Ching Wang
SMSheng-Hsiang Ma
Sheng-Hsiang Ma
YCYun-Ting Chang
Yun-Ting Chang
CCChih-Chiang Chen
Chih-Chiang Chen

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
YLYu-Hsiang Lin
Yu-Hsiang Lin
YWYu-Ching Wang
Yu-Ching Wang
CWChen-Yi Wu
Chen-Yi Wu
YCYun-Ting Chang
Yun-Ting Chang
CCChih-Chiang Chen
Chih-Chiang Chen
Background: Janus kinase inhibitors (JAKis) have revolutionised the management of immune‐mediated inflammatory diseases (IMIDs); however, their potential to increase the risk of herpes zoster (HZ) remains a major concern. Methods: A literature search was performed through February 2024. Phase II, III and IV randomised controlled trials (RCTs) and long‐term extension (LTE) studies comparing JAKis with placebo, methotrexate or tumour necrosis factor inhibitors (TNFis) in IMIDs were included. The primary outcome was the risk ratio (RR) for HZ with JAKis compared to placebo/methotrexate or TNFis. Secondary outcomes included incidence rate ratios (IRRs) for HZ comparing JAKis with active treatments during long‐term follow‐up. Results: A total of 94 RCTs and 30 LTE studies, representing 120,698.3 patient‐years, were included. Pairwise meta‐analysis demonstrated a significantly increased HZ risk with JAKis compared with placebo/methotrexate (RR 1.98, 95% CI 1.56–2.50) and TNFis (RR 2.31, 95% CI 1.73–3.07). Network meta‐analysis identified that in rheumatoid arthritis and psoriatic arthritis, upadacitinib 30 mg significantly increased HZ risk compared with placebo (IRR 2.76, 95% CI 1.58–4.85; IRR 3.54, 95% CI 1.48–8.50) and TNFis (IRR 5.30, 95% CI 3.19–8.81; IRR 10.76, 95% CI 4.78–24.22). In atopic dermatitis, abrocitinib 200 mg was associated with a higher HZ risk compared to placebo (IRR 4.97, 95% CI 1.58–15.60) and dupilumab (IRR 4.85, 95% CI 1.55–15.22). Tofacitinib 10 mg exhibited a higher HZ risk in inflammatory bowel disease compared to placebo (IRR 8.93, 95% CI 1.16–68.53). Patients with atopic dermatitis demonstrated the highest incidence of HZ in both short‐ and long‐term analyses. The risk of HZ was dose‐dependent across all conditions. Conclusions: JAKi use was significantly associated with an elevated HZ risk in IMIDs, demonstrating a consistent dose–response relationship. These findings emphasise the importance of HZ vaccination before initiating JAKi therapy, particularly for patients on higher doses or long‐term treatment.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
PCPin-Chun Chen
Pin-Chun Chen
CCChih-Chiang Chen
Chih-Chiang Chen
SMSheng-Hsiang Ma
Sheng-Hsiang Ma
TCTai-Li Chen
Tai-Li Chen
Introduction: Genodermatoses are rare inherited skin disorders with limited treatment options. Emerging evidence suggests Janus kinase (JAK) inhibitors may offer therapeutic benefits by modulating underlying immune and inflammatory pathways. This study aims to systematically review the efficacy and safety of JAK inhibitors in treating genodermatoses, including epidermolysis bullosa (EB), Netherton syndrome, and Hailey‐Hailey disease. Methods: A comprehensive literature search identified case reports and series evaluating JAK inhibitor therapy in genodermatoses. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal Tools for Case Reports, demonstrating high methodological quality across included studies. Results: Twenty studies involving patients with EB subtypes (especially dystrophic EB), Netherton syndrome, and other inherited dermatoses reported clinical improvement following treatment with JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. Outcomes included reduction in pruritus, skin inflammation, and lesion severity, with notable improvements in quality‐of‐life measures. Treatment regimens varied (e.g., tofacitinib 5 mg twice daily, baricitinib 2 mg once daily, and upadacitinib 15 mg once daily) with follow‐up ranging from weeks to months. Laboratory monitoring showed stable profiles without significant adverse events. Reports of adverse events were rare or absent across studies, indicating favorable safety profiles. Conclusions: JAK inhibitors represent a promising therapeutic avenue for genodermatoses characterized by immune dysregulation and chronic inflammation. While preliminary data are encouraging, further controlled studies are warranted to establish long‐term efficacy and safety. These findings support expanded clinical investigation of JAK inhibition in managing inherited skin disorders.

22 September 2026 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
YHYi-Hsin Ho
Yi-Hsin Ho
TCTe-Wei Chang
Te-Wei Chang
CHChun-Wei Hsu
Chun-Wei Hsu
YHYi-Yun Ho
Yi-Yun Ho
CCChih-Chiang Chen
Chih-Chiang Chen
CLChing-Po Lin
Ching-Po Lin
Postoperative scars may impair quality of life. Prophylactic botulinum toxin type A (BoNT-A) may reduce scarring, but optimal timing, dose density, injection plane, and anatomic indications remain uncertain. This systematic review and meta-analysis evaluated prophylactic BoNT-A for postoperative scar prevention and examined effect modification by timing, dose density, and anatomic site; injection-plane practices were summarized descriptively. Four databases were searched through January 2026 for comparative trials of perioperative or postoperative BoNT-A administration. Random-effects meta-analysis used standardized mean differences (SMDs); subgroup analyses and meta-regression examined timing, dose density, and anatomic site. Seventeen studies (656 treatment sites; 456 participants) were included. BoNT-A improved clinician composite scores (SMD, −0.864; 95% CI, −1.137 to −0.591; low certainty), clinician VAS (SMD, −0.951; 95% CI, −1.468 to −0.434; very low certainty), and objective scar width (SMD, −0.924; 95% CI, −1.119 to −0.728; moderate certainty). Exploratory pooled analyses using the original study-level timing assignments suggested a larger effect with delayed injection (SMD, −1.240; moderate certainty) than with immediate injection (SMD, −0.559; low certainty). Timing and anatomic site jointly accounted for 81% of heterogeneity (P = .0008), with effects largest in chest and smallest in fine facial sites. Moderate-certainty evidence supports reduced objective scar width; clinician composite scales improved with low certainty. Pooled clinician-composite analyses suggested larger effects with delayed injection, although direct within-site timing studies have reported conflicting findings. Immediate-injection evidence and patient-reported outcomes remain uncertain, and cross-study dose escalation within 4 to 10 U/cm was not associated with additional benefit. Level of Evidence: 3 (Therapeutic) For image description, please refer to the figure legend and surrounding text.